Shattuck Labs Inc (STTK) Stock Price, Quote & News

Company Profile

Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also...

Industry: Biotechnology

Sector: Healthcare

Phone: 512 900 4690

Website: www.shattucklabs.com

Address:

500 West 5th Street, Suite 1200, Austin, United States

NyseDayTrader Aug. 24 at 7:05 PM

$STTK

0 · Reply

kshonstocks Aug. 24 at 3:35 PM

$STTK one to watch today has a v nice note--STTK--Raymond James analyst Martin Auster initiated coverage of Shattuck Labs with a Strong Buy rating and $18 price target. SL-325 could offer a differentiated approach to the more than $20B IBD market by targeting the more stable DR3 receptor, with encouraging Phase 1 safety, immunogenicity, and durable target-engagement data supporting its potential to outperform TL1A antibodies ahead of Phase 2b Crohn's data in 1H28, the analyst tells investors in a research note. fly

0 · Reply

StockConsultant Aug. 20 at 1:21 PM

$STTK Shattuck Labs stock, watch for a top of range breakout at https://www.stockconsultant.com/?STTK

0 · Reply

prismmarketview Aug. 11 at 3:15 PM

$STTK reported positive Phase 1 results for SL-325, a potentially first-in-class DR3-blocking antibody. In the multiple-ascending-dose cohort, the candidate showed durable DR3 receptor occupancy at all doses and was generally well tolerated. Phase 2b in Crohn’s is next. https://prismmarketview.com/shattuck-labs-q2-2026-sl-325-advances-toward-phase-2-crohns-disease-study/

0 · Reply

StocktwitsEarnings Aug. 11 at 12:15 PM

$STTK Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.12 up 50.00% YoY • Shattuck Labs expects that current cash and cash equivalents and short-term investments of approximately $208.3 million as of June 30, 2026, will be sufficient to fund operations into 2029.

0 · Reply

focafoca99 Aug. 11 at 10:28 AM

$STTK disclosed Q2 2026 results with promising Phase 1 SL-325 data and $208M cash runway into 2029.

0 · Reply

NyseDayTrader Aug. 4 at 6:02 PM

$STTK This is gearing up for a breakout

0 · Reply

IN0V8 Jul. 24 at 2:20 PM

$STTK Opportunity JP Morgan initiates coverage with overweight rating JP Morgan initiates price target $10

0 · Reply

NyseDayTrader Jul. 23 at 10:59 PM

$STTK consolidation at the $6.70 to $7.40 range is real. Waiting for the next leg up.

0 · Reply

StockScanners Jul. 18 at 8:30 AM

$STTK keep watch this holds above 7.27

0 · Reply

Shattuck Labs initiated with a Strong Buy at Raymond James

2026-08-11T15:35:15.000Z - 21 days ago

Shattuck Labs price target lowered to $14 from $18 at H.C. Wainwright

Aug 11, 2026, 7:00 AM EDT - 21 days ago

Shattuck Labs Quarterly report: Q2 2026

Aug 11, 2026, 7:00 AM EDT - 21 days ago

Shattuck Labs Earnings release: Q2 2026

Aug 11, 2026, 7:00 AM EDT - 21 days ago

Shattuck Labs Slides: Corporate presentation

2026-08-11T10:20:32.000Z - 21 days ago

Shattuck Labs reports Q2 EPS (12c), consensus (12c)

2026-07-24T08:45:08.000Z - 5 weeks ago

Shattuck Labs initiated with an Overweight at JPMorgan

2026-07-20T12:15:16.000Z - 6 weeks ago

Shattuck Labs initiated with an Outperform at Leerink

2026-07-20T10:25:43.000Z - 6 weeks ago

Shattuck Labs initiated with an Outperform at Leerink

Jul 14, 2026, 9:00 AM EDT - 7 weeks ago

Shattuck Labs Slides: Corporate presentation

2026-06-10T10:05:44.000Z - 2 months ago

Shattuck Labs 10.9M share Spot Secondary priced at $4.00

Jun 10, 2026, 12:21 AM EDT - 2 months ago

Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering

2026-06-09T20:30:52.000Z - 2 months ago

Shattuck Labs TBA Spot Secondary; price range $4.00-$4.25

2026-06-09T20:20:20.000Z - 2 months ago

Shattuck Labs announces common stock offering, no amount given

Jun 9, 2026, 4:18 PM EDT - 2 months ago

Shattuck Labs, Inc. Announces Proposed Public Offering

Jun 9, 2026, 8:00 AM EDT - 3 months ago

Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update

2026-06-09T09:55:40.000Z - 3 months ago

Shattuck Labs price target raised to $18 from $7 at Citi

2026-06-08T15:20:25.000Z - 3 months ago

Shattuck Labs price target raised to $17 from $14 at Needham

Jun 8, 2026, 8:00 AM EDT - 3 months ago

Shattuck Labs Transcript: Study result

Jun 8, 2026, 8:00 AM EDT - 3 months ago

Shattuck Labs Press release: Study result

Jun 8, 2026, 8:00 AM EDT - 3 months ago

Shattuck Labs Slides: Study result

2026-06-08T10:10:51.000Z - 3 months ago

Shattuck Labs announces Phase 1 results for SL-325

Jun 8, 2026, 6:00 AM EDT - 3 months ago

Shattuck Labs Announces Phase 1 Results for SL-325

Jun 5, 2026, 4:05 PM EDT - 3 months ago

Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8

2026-06-05T09:55:07.000Z - 3 months ago

Citi opens ‘upside 30-day catalyst watch’ on Shattuck into data

2026-06-05T01:05:18.000Z - 3 months ago

Shattuck Labs upgraded to Buy from Neutral at Citi

2026-05-08T13:46:57.000Z - 4 months ago

Shattuck Labs price target raised to $11 from $8 at Wedbush

2026-05-07T16:39:16.000Z - 4 months ago

Shattuck Labs reports Q1 EPS (13c), consensus (13c)

2026-05-07T16:38:04.000Z - 4 months ago

Shattuck Labs sees cash and cash equivalents sufficient into 2029

May 7, 2026, 7:00 AM EDT - 4 months ago

Shattuck Labs Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 months ago

Shattuck Labs Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 months ago

Shattuck Labs Slides: Corporate presentation

May 7, 2026, 6:15 AM EDT - 4 months ago

Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights

Apr 8, 2026, 8:00 AM EDT - 5 months ago

Shattuck Labs Proxy statement: Proxy filing

Apr 8, 2026, 8:00 AM EDT - 5 months ago

Shattuck Labs Proxy statement: Proxy filing

Mar 5, 2026, 7:00 AM EST - 6 months ago

Shattuck Labs Slides: Corporate presentation

Mar 5, 2026, 6:30 AM EST - 6 months ago

Shattuck Labs Annual report: Q4 2025

Mar 5, 2026, 6:30 AM EST - 6 months ago

Shattuck Labs Earnings release: Q4 2025

Mar 5, 2026, 6:15 AM EST - 6 months ago

Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights

Mar 2, 2026, 9:10 AM EST - 6 months ago

Shattuck Labs Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 8:00 AM EST - 6 months ago

Shattuck Labs Announces Participation in Upcoming March Investor Conferences

Feb 6, 2026, 8:30 AM EST - 7 months ago

Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium

Jan 13, 2026, 7:00 AM EST - 8 months ago

Shattuck Labs Registration statement: Registration Filing

Dec 15, 2025, 4:15 PM EST - 9 months ago

Shattuck Labs, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 4, 2025, 8:20 AM EST - 9 months ago

Shattuck Labs Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 10:10 AM EST - 9 months ago

Shattuck Labs Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 20, 2025, 8:00 AM EST - 10 months ago

Shattuck Labs to Participate in Upcoming December Investor Conferences

Nov 6, 2025, 4:30 PM EST - 10 months ago

Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 6, 2025, 7:00 AM EST - 10 months ago

Shattuck Labs Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 10 months ago

Shattuck Labs Quarterly report: Q3 2025

Nov 6, 2025, 2:00 AM EST - 10 months ago

Shattuck Labs Slides: Corporate Presentation

Oct 8, 2025, 10:00 AM EDT - 11 months ago

Shattuck Labs Transcript: The United European Gastroenterology (UEG) Congress UEG Week 2025

Oct 2, 2025, 7:51 AM EDT - 11 months ago

Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel

Sep 18, 2025, 8:00 AM EDT - 1 year ago

Shattuck Labs Registration statement: Registration Filing

Aug 26, 2025, 6:30 AM EDT - 1 year ago

Shattuck Labs Announces Closing of up to $103 Million Private Placement and Appointments to Board of Directors

Aug 21, 2025, 10:17 AM EDT - 1 year ago

Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease

Aug 14, 2025, 4:00 PM EDT - 1 year ago

Shattuck Labs Earnings release: Q2 2025

Aug 14, 2025, 4:00 PM EDT - 1 year ago

Shattuck Labs Quarterly report: Q2 2025

Aug 14, 2025, 6:30 AM EDT - 1 year ago

Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 5, 2025, 6:30 AM EDT - 1 year ago

Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million

Jul 2, 2025, 7:00 AM EDT - 1 year ago

Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism

May 21, 2025, 8:00 AM EDT - 1 year ago

Shattuck Labs Proxy statement: Proxy Filing

May 21, 2025, 8:00 AM EDT - 1 year ago

Shattuck Labs Proxy statement: Proxy Filing

May 1, 2025, 4:20 PM EDT - 1 year ago

Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 1, 2025, 7:00 AM EDT - 1 year ago

Shattuck Labs Slides: Corporate Presentation

Apr 30, 2025, 6:00 PM EDT - 1 year ago

Shattuck Labs Quarterly report: Q1 2025

Apr 30, 2025, 6:00 PM EDT - 1 year ago

Shattuck Labs Earnings release: Q1 2025

Apr 9, 2025, 3:00 PM EDT - 1 year ago

Shattuck Labs Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 2, 2025, 5:00 PM EDT - 1 year ago

Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

Mar 27, 2025, 8:00 AM EDT - 1 year ago

Shattuck Labs Slides: Corporate presentation

Mar 27, 2025, 7:00 AM EDT - 1 year ago

Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

Mar 26, 2025, 7:00 PM EDT - 1 year ago

Shattuck Labs Earnings release: Q4 2024

Mar 26, 2025, 7:00 PM EDT - 1 year ago

Shattuck Labs Annual report: Q4 2024

Feb 20, 2025, 9:00 AM EST - 1 year ago

Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

Feb 13, 2025, 4:30 PM EST - 1 year ago

Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

Feb 4, 2025, 7:00 AM EST - 1 year ago

Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis Congress

Jan 16, 2025, 10:30 AM EST - 1 year ago

Shattuck Labs Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 6, 2025, 4:59 PM EST - 1 year ago

Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 2, 2025, 7:00 AM EST - 1 year ago

Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025

Dec 4, 2024, 8:45 AM EST - 1 year ago

Shattuck Labs Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Dec 3, 2024, 12:30 PM EST - 1 year ago

Shattuck Labs Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 14, 2024, 7:00 AM EST - 1 year ago

Shattuck Labs Quarterly report: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

Shattuck Labs Earnings release: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

Shattuck Labs Slides: Corporate presentation

Oct 1, 2024, 12:23 PM EDT - 2 years ago

Shattuck Labs' stock craters as biotech scraps main product candidate after failed trial

Oct 1, 2024, 8:00 AM EDT - 2 years ago

Shattuck Labs Transcript: Study Update

Oct 1, 2024, 8:00 AM EDT - 2 years ago

Shattuck Labs Press release: Study Update

Oct 1, 2024, 8:00 AM EDT - 2 years ago

Shattuck Labs Slides: Study Update

Oct 1, 2024, 7:00 AM EDT - 2 years ago

Shattuck Labs Slides: Corporate Presentation

Oct 1, 2024, 6:30 AM EDT - 2 years ago

Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway

Aug 1, 2024, 9:30 AM EDT - 2 years ago

Shattuck Labs Quarterly report: Q2 2024

Aug 1, 2024, 9:30 AM EDT - 2 years ago

Shattuck Labs Earnings release: Q2 2024

Aug 1, 2024, 7:00 AM EDT - 2 years ago

Shattuck Labs Slides: Corporate Presentation

Jul 30, 2024, 5:00 PM EDT - 2 years ago

Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference

Jul 1, 2024, 6:00 AM EDT - 2 years ago

Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes

Jun 14, 2024, 12:00 PM EDT - 2 years ago

Shattuck Labs Transcript: Study Update

Jun 14, 2024, 12:00 PM EDT - 2 years ago

Shattuck Labs Press release: Study Update

Jun 14, 2024, 12:00 PM EDT - 2 years ago

Shattuck Labs Slides: Study Update

Jun 14, 2024, 6:00 AM EDT - 2 years ago

Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leuk

NyseDayTrader Aug. 24 at 7:05 PM

$STTK

0 · Reply

kshonstocks Aug. 24 at 3:35 PM

0 · Reply

StockConsultant Aug. 20 at 1:21 PM

$STTK Shattuck Labs stock, watch for a top of range breakout at https://www.stockconsultant.com/?STTK

0 · Reply

prismmarketview Aug. 11 at 3:15 PM

0 · Reply

StocktwitsEarnings Aug. 11 at 12:15 PM

0 · Reply

focafoca99 Aug. 11 at 10:28 AM

$STTK disclosed Q2 2026 results with promising Phase 1 SL-325 data and $208M cash runway into 2029.

0 · Reply

NyseDayTrader Aug. 4 at 6:02 PM

$STTK This is gearing up for a breakout

0 · Reply

IN0V8 Jul. 24 at 2:20 PM

$STTK Opportunity JP Morgan initiates coverage with overweight rating JP Morgan initiates price target $10

0 · Reply

NyseDayTrader Jul. 23 at 10:59 PM

$STTK consolidation at the $6.70 to $7.40 range is real. Waiting for the next leg up.

0 · Reply

StockScanners Jul. 18 at 8:30 AM

$STTK keep watch this holds above 7.27

0 · Reply

StockScanners Jul. 17 at 4:51 AM

$STTK reached 7.20

0 · Reply

NyseDayTrader Jul. 16 at 8:09 PM

$HYFT $STTK $SPCX $GSBD Current. LETS GO!!!

0 · Reply

NyseDayTrader Jul. 16 at 8:03 PM

$STTK holding 12k strong on this one

0 · Reply

StockScanners Jul. 16 at 4:19 AM

$STTK keep watch if this holds above 6.59

0 · Reply

AlertsAndNews Jul. 15 at 6:57 PM

$STTK interesting options flow here. ITM strikes got hits a minutes ago.

1 · Reply

NyseDayTrader Jul. 3 at 9:26 AM

Most investors wait for confirmation. By then, the easy money is usually gone. THE OPPORTUNITY ISN’T AFTER EVERYONE AGREES. IT’S BEFORE THEY DO. $HYFT $STTK

0 · Reply

Win4PopPop Jul. 1 at 8:45 PM

$PSKY Look what the UK just did with $GETY & $STTK . UK is a dumpster fire.

0 · Reply

NyseDayTrader Jun. 30 at 2:32 PM

$STTK I'm SUPER bullish on this ticker

0 · Reply

NyseDayTrader Jun. 30 at 1:15 AM

$STTK Anyone else watching STTK? The volume has been anything but normal. You had the 5.5M share day… then Friday drops 12.2M shares. Add in those late-day spikes into the close, and it definitely makes you wonder. Could be funds loading Or… is someone positioning ahead of something bigger? Buyout? 😉 I’m not chasing. I’m already here.

0 · Reply

NyseDayTrader Jun. 29 at 9:15 PM

$STTK Its obvious its how you finish that counts

0 · Reply

StockScanners Jun. 27 at 6:04 PM

$STTK keep watch if this holds above 6.29

0 · Reply

NyseDayTrader Jun. 26 at 8:59 PM

$STTK 12.2 million today!

0 · Reply

Market Cap	706.56M
Revenue (ttm)	1.00M
Net Income (ttm)	-48.81M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-4,881.00%
Debt to Equity Ratio	0.00

Volume	751,200
Avg Vol	1,345,120
Day's Range	N/A - N/A
Shares Out	100.36M
Stochastic %K	14%
Beta	1.08
Analysts	Strong Sell
Price Target	$14.67